Drug side effects
eravacycline Side Effects
The reactions most often reported to the FDA for eravacycline (also sold as Xerava), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 205
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2019 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of eravacycline come from 205 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 205 reports to the FDA Adverse Event Reporting System (FAERS) for eravacycline (Xerava): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
205
Reports Mentioning Death
33
16.1% of reports — not proof the medicine caused the death
Hospitalizations
57
27.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 33 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 13 |
| ACUTE RESPIRATORY DISTRESS SYNDROME | 6 |
| THROMBOCYTOPENIA | 5 |
| BLOOD FIBRINOGEN DECREASED | 4 |
| HYPERTRANSAMINASAEMIA | 4 |
| LACTIC ACIDOSIS | 4 |
| SHOCK | 4 |
| BLASTOMYCOSIS | 3 |
| CONDITION AGGRAVATED | 3 |
| ENTEROCOCCAL INFECTION | 3 |
| MYCOBACTERIUM ABSCESSUS INFECTION | 3 |
| PNEUMONITIS | 3 |
| SEPSIS | 3 |
| SEPTIC SHOCK | 3 |
| DISSEMINATED BLASTOMYCOSIS | 2 |
| PULMONARY BLASTOMYCOSIS | 2 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED | 1 |
Reactions in Hospitalization Reports
Top reactions in 57 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| BLOOD FIBRINOGEN DECREASED | 9 |
| HYPERTRANSAMINASAEMIA | 8 |
| LACTIC ACIDOSIS | 8 |
| THROMBOCYTOPENIA | 8 |
| ACUTE RESPIRATORY DISTRESS SYNDROME | 6 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 6 |
| BLASTOMYCOSIS | 3 |
| BLOOD BILIRUBIN INCREASED | 3 |
| ENTEROCOCCAL INFECTION | 3 |
| NAUSEA | 3 |
| PNEUMONITIS | 3 |
| PROTHROMBIN TIME PROLONGED | 3 |
| SEPSIS | 3 |
| BILIRUBIN CONJUGATED INCREASED | 2 |
| COAGULOPATHY | 2 |
| CONDITION AGGRAVATED | 2 |
| DIARRHOEA | 2 |
Nearby, Related Medications
What the FAERS Data Reveals About eravacycline Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 205 voluntary reports linked to eravacycline and its brand equivalents (Xerava), spanning 2019 through 2025. Of those, 33 (16.1%) listed death as an outcome and 57 (27.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 35% were female and 65% male; age distribution skews toward 45-64, with 45 reports in that bracket. The single most reported reaction is blood fibrinogen decreased with 16 submissions, followed by nausea and thrombocytopenia.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to eravacycline's 205.
Read our methodology - how this data is sourced, computed, and verified.